Lisocabtagene Maraleucel Shows Deep, Durable Responses in Patients with Relapsed or Refractory MZL After at Least Two Previous Lines of Systemic Therapy By Ogkologos - February 19, 2026 152 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the marginal zone lymphoma cohort of the TRANSCEND FL study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Efficacy and Safety of Elranatamab, BCMA-CD3 Bispecific Antibody, in Patients with... August 28, 2023 How Running and Training for a Marathon Helped Me Cope After... August 22, 2023 ESMO Gynaecological Cancers Congress 2024, 20-22 June, Florence, Italy June 6, 2024 FDA Approves New Dosing Regimen for Cetuximab April 13, 2021 Load more HOT NEWS Lawmaker Dad Raises Awareness For RSV, An Illness He’d Never Heard... Paramedical Tattoo Artist Creates Realistic Nipple Tattoos For Breast Cancer Survivors... National Study Examines Genetic Testing to Inform Follow-up Care for Cancer... Kinder and more effective – why childhood cancers need specific treatments
